Submitted for Publication: May 17, 2012; final revision received July 14, 2012; accepted August 9, 2012.
Author Contributions: Dr Acharya had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Conflict of Interest Disclosures: None reported.
Funding/Support: This study is supported by grants R01 EY011221, R01 AI079192 (Dr Fleiszig), and T35 EY07139-18 (Drs Leong, Ghanekar, and Li) from the National Institutes of Health, and grant K23 EY017897 from the National Eye Institute and by a Research to Prevent Blindness Career Development Award (Dr Acharya). The Steroids for Corneal Ulcers Trial was funded by grant U10 EY015114 from the National Eye Institute. The University of California, San Francisco, Department of Ophthalmology is supported by National Eye Institute core grant EY02162, by an unrestricted grant from Research to Prevent Blindness, by the South Asia Research Fund, and by That Man May See, Inc.
Role of the Sponsor: Alcon had no role in the design or conduct of the study; in the collection, analysis, or interpretation of the data; or in the preparation, review, or approval of the manuscript.
Additional Contributions: Alcon provided moxifloxacin (Vigamox) for the trial.